Skip to main content
ATXI logo

ATXI · Avenue Therapeutics, Inc. · Metrics

Track ATXI — free
$0.38 -0.05 (-10.71%) At close · Mar 19
Market Cap
$848,783
Shares
3.29M
Volume · Mar 19 173.84K Avg daily vol (3M) 426.7K

ATXI metrics

38 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.38
Market cap
$848,783

Price action

23 metrics
Price change (1W)
-60.3%
Price change (30D)
—
Price change (3M)
-79.6%
Price change (6M)
-86.1%
Price change (YTD)
-81.3%
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
$12.00
52-week low
$0.38
Change from 52-week high
-96.9%
Change from 52-week low
+0.0%
Annualized volatility
98.6%
Annualized volatility (3M)
—
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
—
RSI (14D)
17.1
Price vs SMA 50
-72.1%
Price vs SMA 200
-83.5%
Avg volume (3M)
426,696
Relative volume
0.4
Average dollar volume
$738,078

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
3.29M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-328.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-219.6%
Trailing 12 months
Net margin
-207.2%
Gross profit (TTM)
—
Operating profit (TTM)
−$2.88M
Net income (TTM)
−$2.79M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.58

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+3.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-182.0%
Debt / equity
—
Current ratio
—
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
7.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$1.52M
Latest balance sheet
Cash & equivalents
$1.52M
Total assets
$1.53M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$2.19M
Capital expenditures (TTM)
—
R&D (TTM)
$916,000
SG&A (TTM)
—
Stock compensation (TTM)
$311,000
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1644963 CUSIP 05360L403 Visit website Investor relations